Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Takeda Pharmaceutical Company ( (TAK) ).
On February 13, 2025, Takeda Pharmaceutical Company released its share repurchase report, covering activities from January 1 to January 31, 2025. The company announced a board-approved plan to repurchase up to 28.5 million shares, with a total repurchase amount capped at 100 billion JPY, from February 17 to May 31, 2025. This strategic move is likely aimed at enhancing shareholder value and optimizing capital allocation. During January, no shares were repurchased, and a total of 12,000 shares were disposed through stock options exercise for 44,542,000 JPY. The impact of this announcement could strengthen Takeda’s market position by signaling confidence in its financial stability and commitment to shareholder returns.
More about Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited, headquartered in Tokyo, Japan, is a global pharmaceutical company with a focus on innovative medicine and healthcare solutions. The company is engaged in developing and marketing pharmaceutical products for various therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases.
YTD Price Performance: 0.08%
Average Trading Volume: 1,899,959
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $41.82B
For an in-depth examination of TAK stock, go to TipRanks’ Stock Analysis page.
